Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04058665 · ClinicalTrials.gov registry record
Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 300
- Enrollment target
NCT04058665: Completed study, sponsored by Johns Hopkins University.
NCT04058665 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04058665 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
Perioperative variables that can be used to create a bundled approach quality improvement protocol to minimize blood loss in spine surgery will be evaluated using retrospective data collection and multivariate analysis of previously performed spinal surgeries at Johns Hopkins Hospital. In particular the investigators are interested in determining whether FloSeal® contributes towards increased control over perioperative bleeding compared to other hemostatic agents for potential inclusion in a future bundled approach.
Primary Outcome
Cubic centimeters (cm\^3) of blood loss throughout the operation.
Interventions
- DEVICE Floseal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-06-18 |
| Est. Completion | 2022-03-01 |
What the finished NCT04058665 record still lists
NCT04058665 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Floseal is the first listed.
NCT04058665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04058665 about?
NCT04058665 is a clinical study titled "Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery". Perioperative variables that can be used to create a bundled approach quality improvement protocol to minimize blood loss in spine surgery will be evaluated using retrospective data collection and multivariate analysis of previously performed spinal surgeries at Johns Hopkins Hospital. In particular...
What is the current status of trial NCT04058665?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2019-06-18. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04058665?
The interventions under investigation include: Floseal (DEVICE).
Who is sponsoring clinical trial NCT04058665?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI